Lumefantrine co-artemether
- Generic Name
- Lumefantrine co-artemether
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C346H378Cl33N11O16
- CAS Number
- 141204-94-6
- Unique Ingredient Identifier
- 5T2U51A0MW
- Background
Lumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum, Malaria in Pregnancy, Uncomplicated Malaria, and Uncomplicated Knowlesi Malaria. Lumefantrine Co-Artemether is a tablet formulation of artemether and lumefantrine, a well-tolerated, fast-acting and effective blood schizontocidal drug that serves prima...
- Associated Conditions
- -
- Associated Therapies
- -
Essential Malaria Drug Artemisinin Shows Signs of Partial Resistance in Children
A study in Uganda found partial artemisinin resistance in children with severe malaria, linked to the A675V mutation in the Plasmodium falciparum parasite, impacting standard treatment efficacy.
Azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD)
A phase I/II trial compared 3 azithromycin doses in children with severe malaria, randomizing 105 cases to 10, 15, or 20 mg/kg over 5 days, while 50 controls received standard care. The study aimed to determine optimal azithromycin doses for future trials, with co-primary outcomes of CRP change and microbiological cure. Results showed similar CRP reductions across doses, with no significant differences in survival or adverse events. Pharmacokinetic analysis suggested allometric dosing for consistent exposure, contrasting with the trial's mg/kg regimens.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath